Millennium Boosts Bristol Myers as Stock Breaks Higher
Bristol Myers Squibb shares have climbed to fresh highs as Israel “Izzy” Englander’s Millennium Management sharply increased its position, even as many Wall Street analysts remain cautious on the drugmaker’s near-term outlook.
The stock closed at $62.09 on July 24, up from $45.26 at the start of October, a gain of nearly 37% that has pushed it above both its 50-day moving average of $57.02 and 200-day average of $54.02. Momentum has strengthened with the shares trading near the upper end of their Bollinger Band range, while a 70.3 RSI reading suggests the move has been powerful enough to flirt with technically overbought territory.
That backdrop matters because Bristol Myers is still widely viewed as a company facing multiple pressures, including pricing scrutiny, patent expiry risk and the need to prove that its post-Revlimid growth engines can offset legacy-drug erosion. The company’s April 30 10-Q flagged continued regulatory pressure on prescription drugs and lower reimbursement rates, the kind of operating headwinds that usually make hedge fund conviction a closely watched signal.
Englander’s 780% increase in the stake is what makes the latest filing stand out. Millennium is effectively betting that Wall Street is underestimating Bristol Myers’ ability to defend cash flow, support its dividend and stabilize earnings as the portfolio shifts toward newer therapies.
The stock’s recent trading pattern supports that investors are already leaning into the turnaround case. Bristol Myers has held above its 50-day average for most of the summer, regained momentum after a brief pullback in early July and posted a strong move into the $60s ahead of the latest filing-driven attention.
Still, analysts are not as enthusiastic as the billionaire manager. The gap between hedge fund buying and cautious sell-side sentiment suggests the market is now debating whether Bristol Myers is a value trap with legal and pricing overhangs, or a durable income play with improving operating leverage.
What happens next will likely depend on whether the company can keep earnings momentum intact through the rest of 2026, when investors will be watching for updates on pipeline execution, pricing discipline and any further signs that large institutional buyers are willing to front-run a re-rating.
| Entity | Gains | Losses |
|---|---|---|
| Millennium Management / Izzy Englander | ▲Exposure to a rising defensive pharma name | ▼Risk if turnaround stalls |
| Bristol Myers Squibb bulls | ▲Potential rerating and dividend support | ▼Higher valuation if growth disappoints |
| Cautious analysts | ▲Opportunity to reassess thesis | ▼Missed upside if stock keeps climbing |
| Short sellers / skeptics | ▲None if fundamentals improve | ▼Pain from continued momentum in BMY |